Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men.

Frank Romanelli, Kelly M. Smith, Claire Pomeroy

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Club drugs such as methylenedioxymethamphetamine (MDMA, ecstasy), gamma hydroxybutyrate (GHB), and ketamine are among the fastest-growing drugs of abuse in the United States. Reports have shown that some gay and bisexual men are likely to engage in club-drug use in a myriad of venues. This is concerning given that the use of club drugs has been linked to high-risk sexual behaviors. Further, the use of club drugs by HIV-seropositive individuals may have detrimental outcomes on disease progression by either influencing adherence, resulting in drug-drug interactions with antiretrovirals, or potentially compounding immune suppression. Clinicians caring for HIV-seropositive and -seronegative individuals should be aware of the clinical effects and management guidelines associated with these chemicals. This article reviews the available literature with regard to the use of club drugs by HIV-seropositive and -seronegative gay and bisexual men. Although club-drug use may be associated with many risk behaviors for HIV infection, this review focuses on risk behavior among gay and bisexual men since this is the group for which the most data have been reported. The clinical effects and management guidelines associated with these agents are described, and the potential detrimental effects of these substances on HIV disease are discussed.

Original languageEnglish (US)
Pages (from-to)25-32
Number of pages8
JournalTopics in HIV medicine : a publication of the International AIDS Society, USA
Volume11
Issue number1
StatePublished - 2003
Externally publishedYes

Fingerprint

HIV
Pharmaceutical Preparations
Risk-Taking
N-Methyl-3,4-methylenedioxyamphetamine
Guidelines
Sodium Oxybate
Ketamine
Street Drugs
Sexual Minorities
Drug Interactions
Sexual Behavior
HIV Infections
Disease Progression

Cite this

Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. / Romanelli, Frank; Smith, Kelly M.; Pomeroy, Claire.

In: Topics in HIV medicine : a publication of the International AIDS Society, USA, Vol. 11, No. 1, 2003, p. 25-32.

Research output: Contribution to journalArticle

@article{57e53d410dd743c6af2ccda8e6c3f31e,
title = "Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men.",
abstract = "Club drugs such as methylenedioxymethamphetamine (MDMA, ecstasy), gamma hydroxybutyrate (GHB), and ketamine are among the fastest-growing drugs of abuse in the United States. Reports have shown that some gay and bisexual men are likely to engage in club-drug use in a myriad of venues. This is concerning given that the use of club drugs has been linked to high-risk sexual behaviors. Further, the use of club drugs by HIV-seropositive individuals may have detrimental outcomes on disease progression by either influencing adherence, resulting in drug-drug interactions with antiretrovirals, or potentially compounding immune suppression. Clinicians caring for HIV-seropositive and -seronegative individuals should be aware of the clinical effects and management guidelines associated with these chemicals. This article reviews the available literature with regard to the use of club drugs by HIV-seropositive and -seronegative gay and bisexual men. Although club-drug use may be associated with many risk behaviors for HIV infection, this review focuses on risk behavior among gay and bisexual men since this is the group for which the most data have been reported. The clinical effects and management guidelines associated with these agents are described, and the potential detrimental effects of these substances on HIV disease are discussed.",
author = "Frank Romanelli and Smith, {Kelly M.} and Claire Pomeroy",
year = "2003",
language = "English (US)",
volume = "11",
pages = "25--32",
journal = "Topics in antiviral medicine",
issn = "2161-5861",
publisher = "International Antiviral Society",
number = "1",

}

TY - JOUR

T1 - Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men.

AU - Romanelli, Frank

AU - Smith, Kelly M.

AU - Pomeroy, Claire

PY - 2003

Y1 - 2003

N2 - Club drugs such as methylenedioxymethamphetamine (MDMA, ecstasy), gamma hydroxybutyrate (GHB), and ketamine are among the fastest-growing drugs of abuse in the United States. Reports have shown that some gay and bisexual men are likely to engage in club-drug use in a myriad of venues. This is concerning given that the use of club drugs has been linked to high-risk sexual behaviors. Further, the use of club drugs by HIV-seropositive individuals may have detrimental outcomes on disease progression by either influencing adherence, resulting in drug-drug interactions with antiretrovirals, or potentially compounding immune suppression. Clinicians caring for HIV-seropositive and -seronegative individuals should be aware of the clinical effects and management guidelines associated with these chemicals. This article reviews the available literature with regard to the use of club drugs by HIV-seropositive and -seronegative gay and bisexual men. Although club-drug use may be associated with many risk behaviors for HIV infection, this review focuses on risk behavior among gay and bisexual men since this is the group for which the most data have been reported. The clinical effects and management guidelines associated with these agents are described, and the potential detrimental effects of these substances on HIV disease are discussed.

AB - Club drugs such as methylenedioxymethamphetamine (MDMA, ecstasy), gamma hydroxybutyrate (GHB), and ketamine are among the fastest-growing drugs of abuse in the United States. Reports have shown that some gay and bisexual men are likely to engage in club-drug use in a myriad of venues. This is concerning given that the use of club drugs has been linked to high-risk sexual behaviors. Further, the use of club drugs by HIV-seropositive individuals may have detrimental outcomes on disease progression by either influencing adherence, resulting in drug-drug interactions with antiretrovirals, or potentially compounding immune suppression. Clinicians caring for HIV-seropositive and -seronegative individuals should be aware of the clinical effects and management guidelines associated with these chemicals. This article reviews the available literature with regard to the use of club drugs by HIV-seropositive and -seronegative gay and bisexual men. Although club-drug use may be associated with many risk behaviors for HIV infection, this review focuses on risk behavior among gay and bisexual men since this is the group for which the most data have been reported. The clinical effects and management guidelines associated with these agents are described, and the potential detrimental effects of these substances on HIV disease are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0037980186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037980186&partnerID=8YFLogxK

M3 - Article

C2 - 12717048

AN - SCOPUS:0037980186

VL - 11

SP - 25

EP - 32

JO - Topics in antiviral medicine

JF - Topics in antiviral medicine

SN - 2161-5861

IS - 1

ER -